Abstract: The present disclosure relates to methods of treating dry age-related macular degeneration (dry AMD), comprising administering to a subject in need thereof, a therapeutically effective amount of a compound or pharmaceutical composition according to any embodiment described herein.

Abstract: One embodiment is directed to a computer program, embodied on a computer readable medium. The computer program is configured to control a processor to execute instructions. The instructions include sampling a plurality of points that lie within the interior of an arbitrary shape, drawing one or more rectangles from each of the points, gradually increasing the length and width of the rectangles until the rectangles no longer falls within the interior of the arbitrary shape, and assigning the largest of the increased rectangles as the interior bounding box.

Abstract: One embodiment is directed to a computer program, embodied on a computer readable medium. The computer program is configured to control a processor to execute instructions. The instructions include receiving one or more files as input. The files may each include descriptions of different shapes. The instructions may further include interpreting each of the files as a layer of shapes, converting each of the shapes into an interactive element, layering the converted shapes onto one another to create a custom interactive display, and displaying the custom interactive display.

Abstract: A system navigates among visual elements of a user interface. The system receives a keystroke indicating navigating from a current visual element in a first direction, determines a next visual element that is substantially near the current visual element and in the first direction, and navigates to the next visual element.

Abstract: An automatic testing application is provided that can simulate a user interaction with a web application. The automatic testing application can determine that the web application has been completely displayed within a graphical user interface of a web browser using a consistent global page state. The automatic testing application can test that the web application has been correctly displayed by verifying a state of a visualization component of the web application using a communication component. Subsequently, the automatic testing application can transmit an event to the web application that can modify the state of the visualization component using the communication component.

Abstract: One embodiment is directed to a computer program, embodied on a computer readable medium. The computer program is configured to control a processor to execute instructions. The instructions include receiving one or more files as input. The files may each include descriptions of different shapes. The instructions may further include interpreting each of the files as a layer of shapes, converting each of the shapes into an interactive element, layering the converted shapes onto one another to create a custom interactive display, and displaying the custom interactive display.

Abstract: One embodiment is directed to a computer program, embodied on a computer readable medium. The computer program is configured to control a processor to execute instructions. The instructions include sampling a plurality of points that lie within the interior of an arbitrary shape, drawing one or more rectangles from each of the points, gradually increasing the length and width of the rectangles until the rectangles no longer falls within the interior of the arbitrary shape, and assigning the largest of the increased rectangles as the interior bounding box.

Abstract: A system navigates among visual elements of a user interface. The system receives a keystroke indicating navigating from a current visual element in a first direction, determines a next visual element that is substantially near the current visual element and in the first direction, and navigates to the next visual element.

Abstract: An automatic testing application is provided that can simulate a user interaction with a web application. The automatic testing application can determine that the web application has been completely displayed within a graphical user interface of a web browser using a consistent global page state. The automatic testing application can test that the web application has been correctly displayed by verifying a state of a visualization component of the web application using a communication component. Subsequently, the automatic testing application can transmit an event to the web application that can modify the state of the visualization component using the communication component.

Abstract: The present invention provides novel compounds and pharmaceutical compositions thereof, as well as methods for using the compounds and pharmaceutical compositions for treating tumors. Examples of specific tumor types that the compounds may be used to treat include, but are not limited to sarcomas, melanomas, neuroblastomas, carcinomas (including but not limited to lung, renal cell, ovarian, liver, bladder, and pancreatic carcinomas), and mesotheliomas.

Abstract: The present invention provides novel compounds and pharmaceutical compositions thereof, as well as methods for using the compounds and pharmaceutical compositions for treating tumors. Examples of specific tumor types that the compounds may be used to treat include, but are not limited to sarcomas, melanomas, neuroblastomas, carcinomas (including but not limited to lung, renal cell, ovarian, liver, bladder, and pancreatic carcinomas), and mesotheliomas.

Abstract: The present invention provides novel compounds and pharmaceutical compositions thereof, as well as methods for using the compounds and pharmaceutical compositions for treating tumors. Examples of specific tumor types that the compounds may be used to treat include, but are not limited to sarcomas, melanomas, neuroblastomas, carcinomas (including but not limited to lung, renal cell, ovarian, liver, bladder, and pancreating carcinomas) and mesotheliomas.

Abstract: This invention describes compounds and pharmaceutical compositions useful as ubiquitin agent inhibitors. The compounds and pharmaceutical compositions of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved. The invention also comprises the use of the compounds and pharmaceutical compositions of the invention for the treatment of conditions that require inhibition of ubiquitination. Furthermore, the invention comprises methods of inhibiting ubiquitination in a cell comprising contacting a cell in which inhibition of ubiquitination is desired with a pharmaceutical composition according to the invention.

Abstract: The present invention provides compounds that are effective against inhibiting topoisomerase (i.e., topoisomerase I and/or topoisomerase II). These compounds are used for treating cell-proliferative disorders. In some instances, these compounds have anticancer activity, e.g., against multi-drug resistant cancers.

Abstract: The present invention provides N-aryl piperidine compounds having antiinfective activity (i.e., antibacterial, antiviral), their compositions and methods of use. The compounds of the invention prevent the entry of HIV into host cells. More particularly, the compounds are effective at in inhibiting the binding interaction of HIV glycoprotein gp120 and the cell surface receptor CD4. The compounds can be used alone or in combination with other antivirals, antiinfectives, immunomodulators, or HIV entry inhibitors. More particularly, the invention relates to the prevention and treatment of HIV infectivity and AIDS.

Abstract: This invention describes compounds and pharmaceutical compositions useful as ubiquitin agent inhibitors, particularly ubiquitin ligase inhibitors. The compounds and pharmaceutical compositions of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved, such as signal transduction pathways. The invention also comprises the use of the compounds and pharmaceutical compositions of the invention for the treatment of conditions that require inhibition of ubiquitination. Furthermore, the invention comprises methods of inhibiting ubiquitination in a cell comprising contacting a cell in which inhibition of ubiquitination is desired with a compound or pharmaceutical composition according to the invention. Particularly, the compounds and pharmaceutical compositions are useful to inhibit the ubiquitin ligase activity of TRAF6.

Abstract: This invention describes compounds and pharmaceutical compositions useful as ubiquitin agent inhibitors. The compounds and pharmaceutical compositions of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved. The invention also comprises the use of the compounds and pharmaceutical compositions of the invention for the treatment of conditions that require inhibition of ubiquitination. Furthermore, the invention comprises methods of inhibiting ubiquitination in a cell comprising contacting a cell in which inhibition of ubiquitination is desired with a pharmaceutical composition according to the invention.

Abstract: This invention describes compounds useful as ubiquitin ligase inhibitors. The compounds of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved. The invention also provides for pharmaceutical compositions comprising the compounds described in the invention for the treatment of conditions that require inhibition of ubiquitin ligases. Furthermore, the invention provides for methods of inhibiting ubiquitination in a cell comprising contacting a cell in which inhibition of ubiquitination is desired with a compound according to the invention.